Adherex Licenses GSK’s Eniluracil, Estimates Oncologic’s Potential At $1 Bil.
This article was originally published in Pharmaceutical Approvals Monthly
Adherex gains rights to GlaxoSmithKline's oncology agent eniluracil in exchange for a GSK option on Adherex' lead biotechnology oncologic ADH-1 under a combined licensing agreement, announced July 15
You may also be interested in...
Adherex believes it has identified ways to optimize its chemotherapy enhancing agent eniluracil for use in combination with 5-fluorouracil
Redeeming a priority review voucher obtained by developing a drug for a tropical disease will cost companies $6.1 million in fiscal 2011